The joint agreement resolves all legal disputes between the two companies, including those relating to UCB’s pegylated humanized antibody fragment, Cimzia (certolizumab pegol), and PDL’s Queen et al. patents.
According to the settlement terms, PDL has provided UCB a covenant not to sue the latter for any royalties regarding UCB’s Cimzia product under the Queen patent portfolio in return for a lump sum payment of $10m and the mutual resolution of other disputes between the two companies.
This includes two pending patent interferences before the US Patent and Trademark Office and a patent opposition in the European Patent Office.
No additional payments will be owed by UCB to PDL under the Queen patents in respect of Cimzia sales.